Celltrion’s self-injectable formulation of infliximab, ‘Remsima SC,’ has solidified its position in the European market, capturing a 22% market share as of the end of last year. The drug, used for treating autoimmune diseases, continues to demonstrate strong sales performance.
According to data from IQVIA, the market research firm, Remsima SC’s market share has grown remarkably since its European launch in 2020. In the first year, 2021, it accounted for only 4%, but over the past four years, this figure has increased more than fivefold.
Moreover, the entire Remsima product line—including the intravenous (IV) formulation ‘Remsima’—held a commanding 71% share by the end of last year. This dominant presence indicates that nearly 7 out of every 10 patients prescribed infliximab in Europe are using Celltrion’s products.
The success stems from the convenience of self-injection and high preferences among both healthcare providers and patients. Building on this momentum, expectations are high for the sales outlook of ‘Zymfentra’ (the U.S. product name for Remsima SC), which is currently available in the United States. Considering the stabilizing prescription trends in Europe, once major U.S. insurance providers include Zymfentra in their formularies, prescriptions are anticipated to rise sharply.
Celltrion’s other autoimmune disease treatments are also making notable inroads into Europe. The adalimumab biosimilar ‘Yuflyma,’ introduced to the market in late 2021, achieved a 21% market share by the end of last year—ranking among the top products in just two years since its debut.
Similarly, the ustekinumab biosimilar ‘Steqeyma,’ launched in Europe in October last year, quickly gained over 2% market share within two months, thanks to tailored marketing strategies adapted to the characteristics of each country’s pharmaceutical market.
Beyond immunology, Celltrion’s oncology portfolio is also performing well. ‘Vegzelma,’ launched in Europe in late 2022, despite entering the market two to three years later than competitors, achieved a 28% market share by the end of 2023, ranking first among nine bevacizumab-based products.
Celltrion’s key cancer treatments ‘Truxima’ (rituximab) and ‘Herzuma’ (trastuzumab) have maintained nearly 30% market share each, continuing stable prescription figures. The company plans to leverage marketing synergies among these oncology products to generate further results.
A Celltrion spokesperson stated, “The combined effects of ease of administration, proven treatment efficacy, and tailored sales strategies by our local affiliates are rapidly expanding Remsima SC’s market influence in Europe. We anticipate these successes will translate into positive results in the world’s largest pharmaceutical market, the United States, as well.”
